Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

BACKGROUND: Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Vithayathil, Mathew, D’Alessio, Antonio, Fulgenzi, Claudia Angela Maria, Nishida, Naoshi, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Saeed, Anwaar, Wietharn, Brooke, Hildebrand, Hannah, Wu, Linda, Ang, Celina, Marron, Thomas U., Weinmann, Arndt, Galle, Peter R., Bettinger, Dominik, Bengsch, Bertram, Vogel, Arndt, Balcar, Lorenz, Scheiner, Bernhard, Lee, Pei-Chang, Huang, Yi-Hsiang, Amara, Suneetha, Muzaffar, Mahvish, Naqash, Abdul Rafeh, Cammarota, Antonella, Zanuso, Valentina, Pressiani, Tiziana, Pinter, Matthias, Cortellini, Alessio, Kudo, Masatoshi, Rimassa, Lorenza, Pinato, David J., Sharma, Rohini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386929/
https://www.ncbi.nlm.nih.gov/pubmed/37005953
http://dx.doi.org/10.1007/s12072-023-10491-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386929/
https://www.ncbi.nlm.nih.gov/pubmed/37005953
http://dx.doi.org/10.1007/s12072-023-10491-3

Ejemplares similares